Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.44USD
14 Dec 2018
Change (% chg)

$0.02 (+3.68%)
Prev Close
$0.42
Open
$0.44
Day's High
$0.47
Day's Low
$0.43
Volume
79,097
Avg. Vol
47,883
52-wk High
$3.08
52-wk Low
$0.37

Latest Key Developments (Source: Significant Developments)

ContraVir Pharmaceuticals Appointed Robert Foster As A Director Of Co On Nov 6 - SEC Filing
Tuesday, 13 Nov 2018 05:38pm EST 

Nov 13 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS SAYS ON NOV 6, BOARD REMOVED 'ACTING' FROM ROBERT FOSTER'S TITLE AS CEO; APPOINTED FOSTER AS A DIRECTOR OF CO - SEC FILING.  Full Article

Contravir Pharma Files For Series C Convertible Preferred Stock
Friday, 18 May 2018 04:45pm EDT 

May 18 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING.  Full Article

Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock
Friday, 9 Mar 2018 01:51pm EST 

March 9 (Reuters) - Contravir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING.  Full Article

ContraVir Pharmaceuticals Reaches Agreement With The FDA
Monday, 12 Feb 2018 06:00am EST 

Feb 12 (Reuters) - Contravir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY.CONTRAVIR PHARMACEUTICALS - FDA ALLOWS CO TO USE 505(B)(2) REGULATORY PATHWAY TO STREAMLINE DEVELOPMENT & REGISTRATION OF TXL FOR TREATING CHRONIC HEPATITIS B.  Full Article

Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.
Monday, 11 Sep 2017 06:00am EDT 

Sept 11 (Reuters) - Contravir Pharmaceuticals Inc ::Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States.Contravir Pharmaceuticals - ‍intends to initiate U.S.-based clinical trial for txl in q4 of 2017, pending approval by institutional review board​.Contravir Pharmaceuticals - ‍ intends to initiate its first us-based clinical trial for txl in Q4 2017, pending approval by institutional review board​.  Full Article

U.K. accepts Contravir Pharma's clinical trial application
Wednesday, 6 Sep 2017 06:00am EDT 

Sept 6 (Reuters) - Contravir Pharmaceuticals Inc :Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.  Full Article

ContraVir Pharma to advance second-gen formulation of Tenofovir Exalidex
Thursday, 4 May 2017 06:00am EDT 

May 4 (Reuters) - Contravir Pharmaceuticals Inc :Contravir pharmaceuticals - contravir to advance second-generation formulation of tenofovir exalidex for treatment of hepatitis b virus (hbv).  Full Article

Contravir Pharmaceuticals says offering of 12 mln common shares priced at $1/ share
Tuesday, 25 Apr 2017 09:00am EDT 

April 25 (Reuters) - Contravir Pharmaceuticals Inc ::Contravir Pharmaceuticals announces pricing of public offering of common stock and warrants.Says offering of 12.0 million common shares priced at $1.00per share.Says intends to use net proceeds from sale of securities to fund research and development activities.  Full Article

Contravir Pharmaceuticals announces proposed public offering of common stock
Monday, 24 Apr 2017 04:01pm EDT 

April 24 (Reuters) - Contravir Pharmaceuticals Inc : :Contravir Pharmaceuticals announces proposed public offering of common stock and warrants.Contravir Pharmaceuticals Inc - intends to use net proceeds from sale of securities to fund research and development activities.  Full Article